(1S,2R,6S)-6-[3-(tert-Butyl-diphenyl-silanyloxy)-benzyl]-1-(4,5-diphenyl-oxazol-2-yl)-cyclohexane-1,2-diol | 223911-60-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1S,2R,6S)-6-[3-(tert-Butyl-diphenyl-silanyloxy)-benzyl]-1-(4,5-diphenyl-oxazol-2-yl)-cyclohexane-1,2-diol
• 英文别名: (1S,2R,6S)-6-[[3-[tert-butyl(diphenyl)silyl]oxyphenyl]methyl]-1-(4,5-diphenyl-1,3-oxazol-2-yl)cyclohexane-1,2-diol
• CAS: 223911-60-2
• 化学式: C₄₄H₄₅NO₄Si
• 分子量: 679.931
• InChiKey: MMCWEHYJUUPXON-FPVMNWFKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.54
• 重原子数：
  50
• 可旋转键数：
  10
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  75.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (1S,2R,6S)-6-[3-(tert-Butyl-diphenyl-silanyloxy)-benzyl]-1-(4,5-diphenyl-oxazol-2-yl)-cyclohexane-1,2-diol 在 对甲苯磺酸 、 原甲酸三甲酯 、 乙酰溴 、 potassium carbonate 作用下， 以 二氯甲烷 、 甲醇 为溶剂， 生成 2-{(1S,2S,6R)-2-[3-(tert-Butyl-diphenyl-silanyloxy)-benzyl]-7-oxa-bicyclo[4.1.0]hept-1-yl}-4,5-diphenyl-oxazole
  参考文献：
  名称：

  Metabolism investigation leading to novel drug design: Orally active prostacyclin mimetics. Part 4

  摘要：

  A metabolism study of FR181157 (1) led to the discovery of new oxazole derivatives as active metabolites. The metabolite 6 with an epoxy ring exhibited high anti-aggregative potency with an IC50 of 5.8 nM and potent binding affinity for the human recombinant IP receptor with a K-i value of 6.1 nM and selectivity for human IP receptor over all other members of the human prostanoid receptor family. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.076
• 作为产物：
  描述：

  2-{(S)-6-[3-(tert-Butyl-diphenyl-silanyloxy)-benzyl]-cyclohex-1-enyl}-4,5-diphenyl-oxazole 在 Sharpless AD-mix-β 作用下， 以90%的产率得到(1S,2R,6S)-6-[3-(tert-Butyl-diphenyl-silanyloxy)-benzyl]-1-(4,5-diphenyl-oxazol-2-yl)-cyclohexane-1,2-diol
  参考文献：
  名称：

  Metabolism investigation leading to novel drug design: Orally active prostacyclin mimetics. Part 4

  摘要：

  A metabolism study of FR181157 (1) led to the discovery of new oxazole derivatives as active metabolites. The metabolite 6 with an epoxy ring exhibited high anti-aggregative potency with an IC50 of 5.8 nM and potent binding affinity for the human recombinant IP receptor with a K-i value of 6.1 nM and selectivity for human IP receptor over all other members of the human prostanoid receptor family. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.076